47 related articles for article (PubMed ID: 10782818)
1. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of AGGF1: Potential association with cutaneous and cardiopulmonary involvements in systemic sclerosis.
Takahashi T; Takahashi T; Ikawa T; Terui H; Takahashi T; Segawa Y; Sumida H; Yoshizaki A; Sato S; Asano Y
J Dermatol; 2024 Apr; ():. PubMed ID: 38619119
[TBL] [Abstract][Full Text] [Related]
3. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study.
Fan JJ; Gu JM; Xiao SY; Jia MY; Han GL
Front Med (Lausanne); 2024; 11():1335758. PubMed ID: 38384414
[TBL] [Abstract][Full Text] [Related]
5. KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.
Chiu YH; Chu CC; Lu CC; Liu FC; Tang SE; Chu SJ; Kuo SY; Chen HC
J Inflamm Res; 2022; 15():2255-2262. PubMed ID: 35422651
[TBL] [Abstract][Full Text] [Related]
6. Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?
Tomassetti S; Colby TV; Wells AU; Poletti V; Costabel U; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211059605. PubMed ID: 34900002
[TBL] [Abstract][Full Text] [Related]
7. Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.
Guiot J; Njock MS; André B; Gester F; Henket M; de Seny D; Moermans C; Malaise MG; Louis R
Sci Rep; 2021 May; 11(1):10882. PubMed ID: 34035374
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
9. Sequential changes of serum KL-6 predict the progression of interstitial lung disease.
Jiang Y; Luo Q; Han Q; Huang J; Ou Y; Chen M; Wen Y; Mosha SS; Deng K; Chen R
J Thorac Dis; 2018 Aug; 10(8):4705-4714. PubMed ID: 30233842
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
11. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
J Thorac Dis; 2017 Feb; 9(2):362-371. PubMed ID: 28275485
[TBL] [Abstract][Full Text] [Related]
12. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
[TBL] [Abstract][Full Text] [Related]
13. Molecular biomarkers in interstitial lung diseases.
De Lauretis A; Renzoni EA
Mol Diagn Ther; 2014 Oct; 18(5):505-22. PubMed ID: 24935523
[TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers of interstitial lung disease in systemic sclerosis.
Lota HK; Renzoni EA
Int J Rheumatol; 2012; 2012():121439. PubMed ID: 22988462
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in systemic sclerosis.
Castro SV; Jimenez SA
Biomark Med; 2010 Feb; 4(1):133-47. PubMed ID: 20387310
[TBL] [Abstract][Full Text] [Related]
16. Interstitial lung disease in systemic sclerosis.
Kaloudi O; Miniati I; Alari S; Matucci-Cerinic M
Intern Emerg Med; 2007 Dec; 2(4):250-5. PubMed ID: 18172592
[TBL] [Abstract][Full Text] [Related]
17. Recent advances on pathogenesis and therapies in systemic sclerosis.
Yazawa N; Fujimoto M; Tamaki K
Clin Rev Allergy Immunol; 2007 Oct; 33(1-2):107-12. PubMed ID: 18064573
[TBL] [Abstract][Full Text] [Related]
18. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease.
Tsukamoto H; Nagafuji K; Horiuchi T; Miyamoto T; Aoki K; Takase K; Henzan H; Himeji D; Koyama T; Miyake K; Inoue Y; Nakashima H; Otsuka T; Tanaka Y; Nagasawa K; Harada M
Ann Rheum Dis; 2006 Apr; 65(4):508-14. PubMed ID: 16126798
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and management of pulmonary fibrosis in scleroderma.
White B
Curr Rheumatol Rep; 2002 Apr; 4(2):108-12. PubMed ID: 11890875
[TBL] [Abstract][Full Text] [Related]
20. Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.
Ashida T; Higashishiba M; Sumimoto Y; Sano T; Miyazato H; Shimada T; Miyatake J; Kawanishi K; Tatsumi Y; Kanamaru A
Int J Hematol; 2001 Dec; 74(4):464-8. PubMed ID: 11794706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
